tuberculosis
Conditions
Interventions
Contezolid Group:1) For patients with severe adverse reactions due to linezolid, Linezolid should be discontinued, and after symptomatic treatment of adverse reactions (about 7 days), Contezolid (800m
Sponsors
Guangzhou Chest Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. 18 years old =75 years old, male or female; 2. 40KG= weight =90KG; 3. Patients with clinically diagnosed rifampicin-resistant pulmonary tuberculosis who do not use oxazolidinone-containing drug therapy and do not have other better alternatives. 4. Patients who have been on an anti-tuberculosis regimen containing linezolid for more than 1 month, have developed thrombocytopenia, anemia, or peripheral neuropathy during treatment, and have been assessed as unsuitable for continued use of linezolid. Or patients who need to use oxazolidinone as an anti-tuberculosis regimen, but are assessed not suitable for linezolid due to a history of myelopathic depression, optic neuritis, peripheral neuropathy, etc.; 5. Test negative for HIV.
Exclusion criteria
Exclusion criteria: 1. Allergic to oxazolidinones; 2. Drug sensitivity showed resistance to linezolid; 3. Severe renal insufficiency (creatinine clearance (CrCl) less than 30 mL/min); 4. Moderate liver function impairment (ALT and/or AST levels above 3 times the upper limit of the laboratory reference value, if temporarily elevated, can be enrolled after treatment recovery); 5. Inability to attend or comply with treatment and accompanying visitors; 6. Have a history of severe cardiovascular disease or are suffering from such disease, such as heart failure, hypertension (poorly controlled blood pressure), arrhythmia or post-myocardial infarction status; 7. Pregnant or lactating women; 8. Hiv-positive or AIDS patients; 9. Patients with a history of allergy to more than 2 drugs; 10. Tuberculosis bacteria drug resistance degree is serious, can not form an effective background program patients; 11. Patients who have undergone clinical drug trials within the past 1 year; 12. Patients who lack self-awareness or are unable to walk; 13. Patients with less than primary education or who are unable to write; 14. Patients with advanced malignant tumors; 15. Patients who refuse to sign informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Phlegm cultivation turned negative; | — |
Secondary
| Measure | Time frame |
|---|---|
| Chest imaging; | — |
Countries
China
Contacts
Public ContactZhang Hong
Guangzhou Chest Hospital
Outcome results
None listed